Deals Of The Week: Mylan/Agila, UCB/Biotie, Jazz/Concert…
Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.
You may also be interested in...
Denmark’s dermatology specialist Leo Pharma has linked up with a U.S. psoriasis patient group, the National Psoriasis Foundation, to target innovation on unmet clinical needs.
Resolve Therapeutics and Takeda Pharmaceuticals have agreed to an option agreement that will add to the Japanese pharma’s immunology pipeline while also providing a path to an eventual exit for the biotech’s investors.
The two biotech companies have teamed up to create a follow-on product to Jazz’s narcolepsy drug, a collaboration that could add to the patent-life of Xyrem and be financially beneficial for both companies.